Challenges in Cervical Cancer Prevention: Real-World Scenario in India
Open accessAbstract
In spite of global falling trends, cervical cancer remains a major healthcare challenge for India, South Asia Association for Regional Cooperation region, and other low- and middle-income countries. Our survey was to document the real-world challenges that still exist in India. A total of 316 eligible and complete responses to the 21 questions were analyzed. Screening of mothers and vaccinating their daughters was considered as the most important strategy to prevent cervical cancer by 65.8% (208/316). Screening was offered to all asymptomatic eligible females by 79% (250/316). Improvement in screening rates requires promoting the national program (67.7%; 214/316), strengthening existing infrastructure (62%; 196/316), regular training of primary healthcare workers (57.6%; 182/316), and increasing awareness among schools and colleges (57.9%; 183/316). Almost all responders (93%; 294/316) wanted to have human papillomavirus (HPV) vaccination included in the national immunization schedule. Cost of vaccine was considered a major roadblock. If it became available at INR 250 per dose, 96.8% (306/316) respondents would recommend it for all eligible patients. With the impending availability of this indigenous tetravalent HPV vaccine jointly produced by Department of Biotechnology, Govt of India and Serum Institute of India, the war against cervical cancer just got easier.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cost is perceived by healthcare providers in India to be a major barrier to HPV vaccine uptake.
“Cost is perceived by healthcare providers in India to be a major barrier to HPV vaccine uptake, [63]”
From Acceptability of HPV vaccination for cervical cancer prevention amongst emerging adult women in rural Mysore, India: a mixed-methods study (2024) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303 · see citing works
Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., Martin, D., Simms, K. T., Bénard, É., Boily, M.-C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30068-4 · Cited by 943 · see citing works
Sankaranarayanan, R., Nene, B. M., Dinshaw, K. A., Mahe, C., Jayant, K., Shastri, S. S., Malvi, S. G., Chinoy, R., Kelkar, R., Budukh, A. M., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21050 · Cited by 206 · see citing works
Flagged first, then by citations
Research works printed but not linked: 9
- [1]Arbyn M Weiderpass E Bruni L Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis Lancet Glob Health 2020 8 02 e191 e203 10.1016/S2214-109X(19)30482-6Erratum in: Lancet Glob Health. 2022 Jan;10(1):e41. PMID: 31812369; PMCID: PMC7025157 31812369 PMC7025157 · DOI
- [2]Sung H Ferlay J Siegel R L Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 03 209 249 33538338
- [3]Parikh P M Maheshwari U Krishna V M Robust protective effect of COVID-19 vaccination in India-results of survey in the midst of pandemic's second wave South Asian J Cancer 2021 10 01 28 31 34430516 PMC8380146
- [5]Singh M Jha R P Shri N Bhattacharyya K Patel P Dhamnetiya D Secular trends in incidence and mortality of cervical cancer in India and its states, 1990-2019: data from the Global Burden of Disease 2019 Study BMC Cancer 2022 22 01 149 10.1186/s12885-022-09232-w 35130853 PMC8819855 · DOI · Paper page
- [7]Van Dyne E A Hallowell B D Saraiya M Establishing baseline cervical cancer screening coverage - India, 2015-2016 MMWR Morb Mortal Wkly Rep 2019 68 01 14 19 https://www.jstor.org/stable/26574351 30629571
- [10](on behalf of FOGSI Expert group). Bhatla N Singhal S Saraiya U Screening and management of preinvasive lesions of the cervix: Good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI) J Obstet Gynaecol Res 2020 46 02 201 214 31814222
- [11]Vidhubala E Niraimathi K Shewade H D Mahadevan S Cervical cancer care continuum in South India: evidence from a community-based screening program J Epidemiol Glob Health 2020 10 01 28 35 32175707 PMC7310805
- [12]Basu P Meheus F Chami Y Hariprasad R Zhao F Sankaranarayanan R Management algorithms for cervical cancer screening and precancer treatment for resource-limited settings Int J Gynaecol Obstet 2017 138 01 26 32 28691336
- [14]Bruni L Saura-Lázaro A Montoliu A HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019 Prev Med 2021 144 106399 10.1016/j.ypmed.2020.106399Erratum in: Prev Med. 2022 Feb;155:106925. PMID: 33388322 33388322 · DOI
Cited by
Sorted by citations
Coursey, K., Muralidhar, K., Srinivas, V., Jaykrishna, P., Begum, F., Ningaiah, N., Lee, S.-J., & Madhivanan, P. (2024) · BMC Public Health · doi:10.1186/s12889-024-19485-8 · Cited by 10 · see citing works
“Cost is perceived by healthcare providers in India to be a major barrier to HPV vaccine uptake, [63] and having an HPV vaccine “freely available from the government sector” would positively impact physicians’ decision to recommend vaccination [64].”
Background
- Authors
- Kaur, S., Sharma, L. M., Mishra, V., Goyal, M. G. B., Swasti, S., Talele, A., & Parikh, P. M.
- Affiliations
- Department of Gynae Oncology, Dharamshila Narayana Super Speciality Hospital, Delhi, India
- Department of Medical Oncology and Clinical Hematology, Mahatma Gandhi Medical College Hospital, Jaipur, Rajasthan, India
- Department of Gynaecology, Ishi Clinic, Prayagraj, Uttar Pradesh, India
- Department of Gynaecology, Command Hospital, Pune, Maharashtra, India
- Max Healthcare (IN)
- Department of Medical Oncology, Apollo Hospital, Navi Mumbai, Maharashtra, India
- Department of Clinical Hematology, Mahatma Gandhi University of Health Sciences and Technology, Jaipur, Rajasthan, India
- Venue
- South Asian Journal of Cancer
- Publisher
- Scientific Scholar
- Published
- 2023-01
- Volume
- 12
- Issue
- 01
- Pages
- 009-016
- ISSN
- 2278-330X (ISSN-L)
- 2278-4306
- PMC
- PMC9966165
- OpenAlex
- W4322097620
- Cited by
- 35
- References
- 3
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 18 · 2023: 3
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- South Asian Journal of Cancer (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- cervical cancer prevention, cervical cancer screening, HPV vaccination, human papillomavirus, national immunization schedule, vaccine cost barriers, India
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
